MTBVAC-based TB-HIV vaccine is safe, elicits HIV-T cell responses, and protects against Mycobacterium tuberculosis in Mice
The tuberculosis (TB) vaccine MTBVAC is the only live-attenuated Mycobacterium tuberculosis (Mtb)-based vaccine in clinical development, and it confers superior protection in different animal models compared to the current vaccine, BCG (Mycobacterium bovis bacillus Calmette-Guérin). With the aim of...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Elsevier
2019
|
| _version_ | 1797091644292464640 |
|---|---|
| author | Broset, E Saubi, N Guitart, N Aguilo, N Uranga, S Kilpeläinen, A Eto, Y Hanke, T Gonzalo-Asensio, J Martín, C Joseph-Munné, J |
| author_facet | Broset, E Saubi, N Guitart, N Aguilo, N Uranga, S Kilpeläinen, A Eto, Y Hanke, T Gonzalo-Asensio, J Martín, C Joseph-Munné, J |
| author_sort | Broset, E |
| collection | OXFORD |
| description | The tuberculosis (TB) vaccine MTBVAC is the only live-attenuated Mycobacterium tuberculosis (Mtb)-based vaccine in clinical development, and it confers superior protection in different animal models compared to the current vaccine, BCG (Mycobacterium bovis bacillus Calmette-Guérin). With the aim of using MTBVAC as a vector for a dual TB-HIV vaccine, we constructed the recombinant MTBVAC.HIVA2auxo strain. First, we generated a lysine auxotroph of MTBVAC (MTBVACΔlys) by deleting the lysA gene. Then the auxotrophic MTBVACΔlys was transformed with the E. coli-mycobacterial vector p2auxo.HIVA, harboring the lysA-complementing gene and the HIV-1 clade A immunogen HIVA. This TB-HIV vaccine conferred similar efficacy to the parental strain MTBVAC against Mtb challenge in mice. MTBVAC.HIVA2auxo was safer than BCG and MTBVAC in severe combined immunodeficiency (SCID) mice, and it was shown to be maintained up to 42 bacterial generations in vitro and up to 100 days after inoculation in vivo. The MTBVAC.HIVA2auxo vaccine, boosted with modified vaccinia virus Ankara (MVA).HIVA, induced HIV-1 and Mtb-specific interferon-γ-producing T cell responses and polyfunctional HIV-1-specific CD8+ T cells producing interferon-γ (IFN-γ), tumor necrosis factor alpha (TNF-α), and CD107a in BALB/c mice. Here we describe new tools to develop combined vaccines against TB and HIV with the potential of expansion for other infectious diseases. |
| first_indexed | 2024-03-07T03:35:57Z |
| format | Journal article |
| id | oxford-uuid:bc461f54-3bb0-4223-890a-a84b2590a599 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T03:35:57Z |
| publishDate | 2019 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:bc461f54-3bb0-4223-890a-a84b2590a5992022-03-27T05:23:22ZMTBVAC-based TB-HIV vaccine is safe, elicits HIV-T cell responses, and protects against Mycobacterium tuberculosis in MiceJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:bc461f54-3bb0-4223-890a-a84b2590a599Symplectic Elements at OxfordElsevier2019Broset, ESaubi, NGuitart, NAguilo, NUranga, SKilpeläinen, AEto, YHanke, TGonzalo-Asensio, JMartín, CJoseph-Munné, JThe tuberculosis (TB) vaccine MTBVAC is the only live-attenuated Mycobacterium tuberculosis (Mtb)-based vaccine in clinical development, and it confers superior protection in different animal models compared to the current vaccine, BCG (Mycobacterium bovis bacillus Calmette-Guérin). With the aim of using MTBVAC as a vector for a dual TB-HIV vaccine, we constructed the recombinant MTBVAC.HIVA2auxo strain. First, we generated a lysine auxotroph of MTBVAC (MTBVACΔlys) by deleting the lysA gene. Then the auxotrophic MTBVACΔlys was transformed with the E. coli-mycobacterial vector p2auxo.HIVA, harboring the lysA-complementing gene and the HIV-1 clade A immunogen HIVA. This TB-HIV vaccine conferred similar efficacy to the parental strain MTBVAC against Mtb challenge in mice. MTBVAC.HIVA2auxo was safer than BCG and MTBVAC in severe combined immunodeficiency (SCID) mice, and it was shown to be maintained up to 42 bacterial generations in vitro and up to 100 days after inoculation in vivo. The MTBVAC.HIVA2auxo vaccine, boosted with modified vaccinia virus Ankara (MVA).HIVA, induced HIV-1 and Mtb-specific interferon-γ-producing T cell responses and polyfunctional HIV-1-specific CD8+ T cells producing interferon-γ (IFN-γ), tumor necrosis factor alpha (TNF-α), and CD107a in BALB/c mice. Here we describe new tools to develop combined vaccines against TB and HIV with the potential of expansion for other infectious diseases. |
| spellingShingle | Broset, E Saubi, N Guitart, N Aguilo, N Uranga, S Kilpeläinen, A Eto, Y Hanke, T Gonzalo-Asensio, J Martín, C Joseph-Munné, J MTBVAC-based TB-HIV vaccine is safe, elicits HIV-T cell responses, and protects against Mycobacterium tuberculosis in Mice |
| title | MTBVAC-based TB-HIV vaccine is safe, elicits HIV-T cell responses, and protects against Mycobacterium tuberculosis in Mice |
| title_full | MTBVAC-based TB-HIV vaccine is safe, elicits HIV-T cell responses, and protects against Mycobacterium tuberculosis in Mice |
| title_fullStr | MTBVAC-based TB-HIV vaccine is safe, elicits HIV-T cell responses, and protects against Mycobacterium tuberculosis in Mice |
| title_full_unstemmed | MTBVAC-based TB-HIV vaccine is safe, elicits HIV-T cell responses, and protects against Mycobacterium tuberculosis in Mice |
| title_short | MTBVAC-based TB-HIV vaccine is safe, elicits HIV-T cell responses, and protects against Mycobacterium tuberculosis in Mice |
| title_sort | mtbvac based tb hiv vaccine is safe elicits hiv t cell responses and protects against mycobacterium tuberculosis in mice |
| work_keys_str_mv | AT brosete mtbvacbasedtbhivvaccineissafeelicitshivtcellresponsesandprotectsagainstmycobacteriumtuberculosisinmice AT saubin mtbvacbasedtbhivvaccineissafeelicitshivtcellresponsesandprotectsagainstmycobacteriumtuberculosisinmice AT guitartn mtbvacbasedtbhivvaccineissafeelicitshivtcellresponsesandprotectsagainstmycobacteriumtuberculosisinmice AT aguilon mtbvacbasedtbhivvaccineissafeelicitshivtcellresponsesandprotectsagainstmycobacteriumtuberculosisinmice AT urangas mtbvacbasedtbhivvaccineissafeelicitshivtcellresponsesandprotectsagainstmycobacteriumtuberculosisinmice AT kilpelainena mtbvacbasedtbhivvaccineissafeelicitshivtcellresponsesandprotectsagainstmycobacteriumtuberculosisinmice AT etoy mtbvacbasedtbhivvaccineissafeelicitshivtcellresponsesandprotectsagainstmycobacteriumtuberculosisinmice AT hanket mtbvacbasedtbhivvaccineissafeelicitshivtcellresponsesandprotectsagainstmycobacteriumtuberculosisinmice AT gonzaloasensioj mtbvacbasedtbhivvaccineissafeelicitshivtcellresponsesandprotectsagainstmycobacteriumtuberculosisinmice AT martinc mtbvacbasedtbhivvaccineissafeelicitshivtcellresponsesandprotectsagainstmycobacteriumtuberculosisinmice AT josephmunnej mtbvacbasedtbhivvaccineissafeelicitshivtcellresponsesandprotectsagainstmycobacteriumtuberculosisinmice |